Ceres Nanosciences has added a $5.5m extension from investors including the LVG Seed Fund to help continue development of its diagnostics test for Lyme disease.
Ceres Nanosciences, a US-based Lyme disease therapy developer based on research from George Mason University, has added $5.5m in series A funding to take the round’s total to $8.5m.
The extension included investments from the university’s LVG Seed Fund along with charitable research agency Bay Area Lyme Foundation and venture capital fund Pactolus Ventures.
Ceres previously received a $3m series A tranche in February 2017 led by VC firm GreyBird Ventures, which is due to provide additional funding on…
